| Size | Price | Stock | Qty |
|---|---|---|---|
| 10mg |
|
||
| 100mg | |||
| 1g | |||
| Other Sizes |
| Targets |
Cleavable Linker
Cyclooctyne-O-PFP ester is classified as a cleavable ADC linker. The compound targets primary amine groups (-NH₂) on antibodies through the PFP ester group. The alkyne group reacts with azide-containing molecules via click chemistry (CuAAc). The cleavable nature of the linker allows for the release of the drug payload at the target site. The compound has a molecular formula of C16H13F5O3 and a molecular weight of 348.27 g/mol. |
|---|---|
| ln Vitro |
ADCs are made up of an antibody and an ADC cytotoxin that are joined together by an ADC linker.
In vitro, Cyclooctyne-O-PFP ester is used for the synthesis of ADCs via click chemistry. The PFP ester group reacts efficiently with primary amines at pH 7-9 to form stable amide bonds. The alkyne group can undergo CuAAc with azide-containing molecules, enabling the attachment of various payloads. The compound’s cleavable nature allows for the release of the drug payload under specific conditions. ADCs are comprised of an antibody to which is attached an ADC cytotoxin through an ADC linker. |
| ln Vivo |
No detailed in vivo activity data for Cyclooctyne-O-PFP ester has been published in the available literature. The compound is a research tool used primarily for the synthesis of ADCs. Its in vivo activity would depend on the specific antibody and payload to which it is conjugated. The cleavable nature of the linker allows for the release of the drug payload at the target site.
|
| Enzyme Assay |
The conjugation efficiency of Cyclooctyne-O-PFP ester can be assessed using various analytical techniques. In a typical conjugation reaction, the antibody is buffer-exchanged into a suitable conjugation buffer. Cyclooctyne-O-PFP ester is dissolved in an appropriate solvent and added to the antibody. The reaction is incubated at room temperature. The degree of conjugation is assessed by MALDI-TOF mass spectrometry or by SDS-PAGE. The click chemistry reaction with azide-containing molecules can be monitored by HPLC or mass spectrometry.
|
| Cell Assay |
The cellular activity of Cyclooctyne-O-PFP ester conjugates is assessed in cell-based assays that depend on the specific antibody and payload. For ADC applications, the antibody-drug conjugate is added to target cells expressing the appropriate antigen. Cell viability is measured using MTT or CellTiter-Glo assays. The specificity of the conjugate for target cells is assessed by comparing activity against antigen-positive and antigen-negative cell lines.
|
| Animal Protocol |
No detailed in vivo animal model data for Cyclooctyne-O-PFP ester has been published in the available literature. The compound is a research tool used in the synthesis of ADCs. Its in vivo efficacy would be evaluated in animal models using the specific ADC to which it is conjugated. Typical studies would involve xenograft models for ADC efficacy.
|
| ADME/Pharmacokinetics |
No detailed pharmacokinetic data for Cyclooctyne-O-PFP ester has been published in the available literature. The compound has a molecular weight of 348.27 g/mol and a molecular formula of C16H13F5O3. The compound has a purity of 95% or higher. Further studies would be needed to characterize the pharmacokinetic properties of Cyclooctyne-O-PFP ester conjugates.
|
| Toxicity/Toxicokinetics |
No detailed toxicity data for Cyclooctyne-O-PFP ester has been published in the available literature. As a research compound used in ADC synthesis, Cyclooctyne-O-PFP ester is not intended for direct therapeutic use. The toxicity of Cyclooctyne-O-PFP ester conjugates would depend on the specific antibody and payload. The compound is typically handled with standard laboratory safety precautions.
|
| References | |
| Additional Infomation |
Cyclooctyne-O-PFP ester (CAS#: 886209-60-5) is a cleavable ADC linker and click chemistry reagent used in the synthesis of antibody-drug conjugates (ADCs). The compound contains an alkyne group for CuAAc click chemistry and a PFP ester group for amine conjugation. It has a molecular weight of 348.27 g/mol and a molecular formula of C16H13F5O3. The compound is used in cancer research for the development of targeted therapies. It is a valuable tool for the synthesis of ADCs and other bioconjugates.
|
| Molecular Formula |
C16H13F5O3
|
|---|---|
| Exact Mass |
348.078
|
| CAS # |
886209-60-5
|
| PubChem CID |
59511122
|
| Appearance |
White to off-white ointment
|
| LogP |
4.2
|
| Hydrogen Bond Donor Count |
0
|
| Hydrogen Bond Acceptor Count |
8
|
| Rotatable Bond Count |
5
|
| Heavy Atom Count |
24
|
| Complexity |
486
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
C1CCC#CC(CC1)OCC(=O)OC2=C(C(=C(C(=C2F)F)F)F)F
|
| InChi Key |
FTKRNGMQMZGSDF-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C16H13F5O3/c17-11-12(18)14(20)16(15(21)13(11)19)24-10(22)8-23-9-6-4-2-1-3-5-7-9/h9H,1-4,6,8H2
|
| Chemical Name |
(2,3,4,5,6-pentafluorophenyl) 2-cyclooct-2-yn-1-yloxyacetate
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : 100 mg/mL (287.14 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.5 mg/mL (7.18 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: 2.5 mg/mL (7.18 mM) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), suspension solution; with ultrasonication. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. View More
Solubility in Formulation 3: ≥ 2.5 mg/mL (7.18 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. |
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
